EyePoint (EYPT) Accumulated Expenses (2011 - 2026)
EyePoint (EYPT) posted Accumulated Expenses of $6.7 million for Q1 2026, down 72.6% sequentially from $24.4 million in Q4 2025, and down 63.24% YoY from $18.2 million in Q1 2025.
Analysis
EyePoint (EYPT) Accumulated Expenses (2011 - 2026) Analysis & Trends
EyePoint has reported Accumulated Expenses for 16 years, with the latest figure at $6.7 million in Q1 2026.
- Quarterly Accumulated Expenses fell 63.24% year-over-year to $6.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $6.7 million (down 63.24% YoY) and the FY2025 annual result came in at $24.4 million, up 34.75% from the prior year.
- Accumulated Expenses eased to $6.7 million in Q1 2026 per EYPT's latest filing, from $24.4 million in the prior quarter.
- Over five years, Accumulated Expenses peaked at $24.4 million in Q4 2025 and troughed at $3.1 million in Q1 2022.
- A 5-year average of $12.3 million and a median of $13.3 million in 2024 frame the typical range for Accumulated Expenses.
- The sharpest annual moves came in 2024 and 2026: Accumulated Expenses soared 274.71% in 2024, then tumbled 63.24% in 2026.
- Over 5 years, Accumulated Expenses stood at $16.4 million in 2022, then retreated by 22.79% to $12.6 million in 2023, then jumped by 43.32% to $18.1 million in 2024, then soared by 34.75% to $24.4 million in 2025, then sank by 72.6% to $6.7 million in 2026.
- According to Business Quant data, Accumulated Expenses over the past three periods registered $6.7 million, $24.4 million, and $10.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | EyePoint | 398.53 Mn | 218.06 Mn | 507,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 22.00 Mn |
| Mar 31, 2026 | 16.44 Mn |
| Dec 31, 2025 | 24.39 Mn |
| Sep 30, 2025 | 17.94 Mn |
| Jun 30, 2025 | 11.48 Mn |
| Mar 31, 2025 | 18.18 Mn |
| Dec 31, 2024 | 18.10 Mn |
| Sep 30, 2024 | 14.17 Mn |
| Jun 30, 2024 | 13.34 Mn |
| Mar 31, 2024 | 15.94 Mn |
| Dec 31, 2023 | 17.52 Mn |
| Sep 30, 2023 | 13.42 Mn |
| Jun 30, 2023 | 15.15 Mn |
| Mar 31, 2023 | 10.49 Mn |
| Dec 31, 2022 | 16.36 Mn |
| Sep 30, 2022 | 16.00 Mn |
| Jun 30, 2022 | 14.31 Mn |
| Mar 31, 2022 | 12.33 Mn |
| Dec 31, 2021 | 14.42 Mn |
| Sep 30, 2021 | 11.46 Mn |